CBLN1: A Potential Drug Target and Biomarker for Cerebellin 1 Precursor

Target Name: CBLN1

NCBI ID: G869

CBLN1

CBLN1: A Potential Drug Target and Biomarker for Cerebellin 1 Precursor

Cerebellin 1 (C1) is a protein that is expressed in various tissues, including the brain, and is involved in the development and maintenance of normal brain function. It is a precursor protein that is processed into its mature form by the enzyme cerebellin 1 precursor (CBLN1). CBLN1 has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia.

The identification of CBLN1 as a potential drug target and biomarker for neurological disorders began with the observation that individuals with certain genetic mutations, such as the APTN3422G mutation, are at increased risk for developing Alzheimer's disease. The APTN3422G mutation is a missense mutation that results in the substitution of the amino acid Asp for Asn at position 3422 in the C1 protein. This mutation has been shown to cause abnormal aggregation of the protein beta-amyloid and to contribute to the development of Alzheimer's disease.

In order to understand the role of CBLN1 in the development and progression of Alzheimer's disease, researchers have studied the effects of drugs that can modulate CBLN1 activity. One such drug is doneanoside A, which is a known inhibitor of CBLN1. Researchers have found that treatment with doneanoside A has been shown to reduce the formation of beta-amyloid plaques in individuals with Alzheimer's disease, a hallmark of the disease.

Another potential drug that can modulate CBLN1 activity is the neurotransmitter dopamine. Dopamine is a chemical that is involved in the transmission of signals in the brain and is often impaired in individuals with Alzheimer's disease. Researchers have found that dopamine can inhibit the activity of CBLN1 and that this inhibition may contribute to the development of the disease.

In addition to its role in the development of Alzheimer's disease, CBLN1 has also been identified as a potential biomarker for the disease. The CBLN1 protein is expressed in various tissues of the brain and has been shown to be decreased in individuals with Alzheimer's disease. This suggests that CBLN1 may be a useful biomarker for the disease and that its levels may be a useful target for drug development.

CBLN1 has also been shown to be involved in the development and progression of other psychiatric disorders, including Parkinson's disease and schizophrenia. In individuals with Parkinson's disease, CBLN1 levels have been found to be decreased and to be associated with the misfolding of the protein alpha-synuclein. In individuals with schizophrenia, CBLN1 levels have been found to be increased and to be associated with the development of positive symptoms, such as hallucinations and delusions.

In conclusion, CBLN1 is a protein that is involved in the development and maintenance of normal brain function and has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and schizophrenia. The identification of CBLN1 as a potential drug target and biomarker for these disorders has the potential to lead to new and more effective treatments for these debilitating conditions. Further research is needed to fully understand the role of CBLN1 in the development and progression of these disorders and to develop safe and effective drugs that can modulate CBLN1 activity.

Protein Name: Cerebellin 1 Precursor

Functions: Required for synapse integrity and synaptic plasticity. During cerebellar synapse formation, essential for the matching and maintenance of pre- and post-synaptic elements at parallel fiber-Purkinje cell synapses, the establishment of the proper pattern of climbing fiber-Purkinje cell innervation, and induction of long-term depression at parallel fiber-Purkinje cell synapses. Plays a role as a synaptic organizer that acts bidirectionally on both pre- and post-synaptic components. On the one hand induces accumulation of synaptic vesicles in the pre-synaptic part by binding with NRXN1 and in other hand induces clustering of GRID2 and its associated proteins at the post-synaptic site through association of GRID2. NRXN1-CBLN1-GRID2 complex directly induces parallel fiber protrusions that encapsulate spines of Purkinje cells leading to accumulation of GRID2 and synaptic vesicles. Required for CBLN3 export from the endoplasmic reticulum and secretion (By similarity). NRXN1-CBLN1-GRID2 complex mediates the D-Serine-dependent long term depression signals and AMPA receptor endocytosis (PubMed:27418511). Essential for long-term maintenance but not establishment of excitatory synapses (By similarity). Inhibits the formation and function of inhibitory GABAergic synapses in cerebellar Purkinje cells (By similarity)

The "CBLN1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CBLN1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets